Key Takeaways 

• State-level affordability oversight is expanding. Prescription Drug Affordability Review Boards (PDABs) now affect millions of covered lives, introducing potential upper payment limits (UPLs) that may influence reimbursement strategy and specialty drug contracting.
• Copay policy shifts are reshaping benefit design. Growing state bans on copay accumulator programs are altering cost-sharing dynamics, requiring plans and employers to reassess deductible structures and financial exposure.
• Affordability pressures are driving strategic recalibration. As PDAB authority and copay regulations evolve, payers and manufacturers must adapt contracting models, access strategies, and regional planning to navigate an increasingly fragmented policy environment.

State-level drug affordability initiatives and evolving copay policies are reshaping the managed care landscape, forcing payers and manufacturers to reassess benefit design, access strategy, and contracting dynamics. As policymakers intensify scrutiny on prescription drug costs, the downstream effects are increasingly operational—not just legislative. These are key themes expected to be spotlighted at the Pharmaceutical Care Management Association (PCMA) 2026 Business Forum.

According to a December 2025 Avalere Health advisory, PDAB policies now affect nearly 8 million commercial and Medicaid lives across multiple states. These boards are empowered to review high-cost drugs and, in some cases, establish UPLs intended to curb excessive pricing.¹

While PDAB authority varies by state, the growing reach of these entities signals a meaningful shift in state-level intervention. For payers, UPL implementation introduces potential reimbursement variability and new administrative considerations, particularly in fully insured commercial and Medicaid managed care markets. For manufacturers, PDAB reviews may influence launch sequencing, pricing strategies, and contracting structures, especially for specialty products with high upfront costs.

At the same time, changes to copay accumulator and maximizer policies are adding further complexity. Avalere reports that state bans on copay accumulator programs now affect at least 17% of commercial lives, limiting the ability of health plans to exclude manufacturer copay assistance from a patient’s deductible calculation.² These bans are intended to reduce patient out-of-pocket burden but can alter actuarial assumptions underlying benefit design.

In response, some employers and plan sponsors have explored alternative funding models to offset financial exposure, including benefit carve-outs and third-party assistance coordination programs. These approaches, while controversial, reflect the broader tension between affordability protections and cost containment. As regulatory oversight intensifies, stakeholders must weigh compliance risk, patient disruption, and long-term sustainability.

Collectively, PDAB expansion and copay policy shifts underscore a broader trend: affordability is increasingly being addressed through state-driven mechanisms rather than solely through federal reform. For managed care leaders, this creates a fragmented policy environment that demands closer monitoring of state legislative activity and proactive scenario planning.

Benefit design decisions are no longer insulated from public policy developments. Instead, they are directly shaped by evolving statutory frameworks that influence reimbursement ceilings, cost-sharing structures, and patient access pathways. Contracting strategies, particularly for specialty therapies, must now account for potential UPL constraints, regional variability, and shifting cost-sharing dynamics.

As affordability initiatives gain momentum, collaboration between payers, pharmacy benefit managers, manufacturers, and policymakers will be essential to maintain access while preserving financial viability. The intersection of PDAB authority, copay regulation, and alternative funding strategies represents a pivotal area of focus for managed care stakeholders navigating today’s complex and rapidly evolving market.

References

1. Porter L, Kruger M, Gooding M. PDABs affect nearly 8 million commercial and Medicaid lives. Avalere Health. Published December 11, 2025. Accessed March 9, 2026. https://advisory.avalerehealth.com/insights/pdabs-affect-nearly-8-million-commercial-and-medicaid-lives
2. Gooding M, Porter L, Klein Z. State copay accumulator bans now affect at least 17% of commercial lives. Avalere Health. Published December 10, 2025. Accessed March 9, 2026. https://advisory.avalerehealth.com/insights/state-copay-accumulator-bans-now-affect-at-least-17-of-commercial-lives